Calidi Biotherapeutics P/E Ratio

Calidi Biotherapeutics (CLDI) currently reports a P/E ratio of -0.02. That is below the sector sector average of 35.43. Use the charts on this page to explore Calidi Biotherapeutics's P/E ratio history and peer comparisons.

Calidi Biotherapeutics's P/E ratio of -0.02 is lower than the its sector sector average of 35.43. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Calidi Biotherapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -0.02, CLDI can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.02, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 35.43. From there, open related valuation or income-statement pages for Calidi Biotherapeutics, and consider following CLDI for alerts when major investors trade the stock.